文献速递核素与放射性配体治疗肿瘤 PET/CT

基于SiPM的PET/CT用于钇-90肝放射栓塞的高质量成像与剂量学

High quality imaging and dosimetry for yttrium-90 (90Y) liver radioembolization using a SiPM-based PET/CT scanner.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-01-14

该前瞻性研究纳入42例晚期肝恶性肿瘤患者,比较治疗前99mTc-MAA SPECT/CT与治疗后90Y PET/CT的肿瘤及正常肝吸收剂量,并评估基于SiPM的90Y PET/CT图像质量。结果显示两种方法剂量学结果无显著差异,90Y PET/CT在10分钟扫描时间图像质量良好,5分钟图像质量可接受且足以用于剂量学和治疗验证。

要点

  • 99mTc-MAA SPECT/CT用于治疗计划剂量学具有良好准确性。
  • 基于SiPM的90Y PET/CT在10分钟扫描时间图像质量良好。
  • 5分钟90Y PET/CT图像质量可接受,足以用于剂量学和治疗验证。

核心结论

  • 99mTc-MAA SPECT/CT在治疗计划剂量学方面表现出良好准确性。
  • 基于SiPM的PET/CT扫描仪在10分钟扫描时间、单床位采集下显示良好图像质量。
  • 5分钟PET/CT扫描图像质量可接受,足以用于剂量学和治疗验证,便于纳入繁忙的常规临床工作流程。

研究设计与样本

  • 前瞻性研究纳入42例晚期肝恶性肿瘤患者(28男14女,平均年龄67±11岁)。
  • 20例接受玻璃微球治疗,22例接受树脂微球治疗。
  • 评估治疗前99mTc-MAA SPECT/CT与治疗后90Y PET/CT的吸收剂量。
  • 90Y PET/CT采集20分钟并重建为5、10、15和20分钟数据集,采用5点Likert量表评估图像质量。

主要发现

  • 玻璃微球平均给药活度为3.44±1.5 GBq,树脂微球为1.62±0.7 GBq。
  • 玻璃微球肿瘤平均吸收剂量:99mTc-MAA SPECT/CT为175.69±113.76 Gy,90Y PET/CT为193.58±111.09 Gy(P=0.61)。
  • 树脂微球肿瘤平均吸收剂量:99mTc-MAA SPECT/CT为60.18±42.20 Gy,90Y PET/CT为70.98±49.65 Gy(P=0.37)。
  • 玻璃微球正常肝平均吸收剂量:99mTc-MAA SPECT/CT为32.70±22.25 Gy,90Y PET/CT为30.62±20.09 Gy(P=0.77)。
  • 树脂微球正常肝平均吸收剂量:99mTc-MAA SPECT/CT为18.33±11.08 Gy,90Y PET/CT为24.32±15.58 Gy(P=0.17)。

关键数值与推荐

  • 90Y PET/CT在5、10、15、20分钟扫描时间的Likert评分分别为3.6±0.54、4.57±0.58、4.84±0.37、4.9±0.3。

临床怎么用

  • 99mTc-MAA SPECT/CT可用于90Y微球治疗计划的剂量学评估。
  • 基于SiPM的90Y PET/CT可在10分钟扫描时间获得良好图像质量,5分钟扫描可接受并足以用于剂量学和治疗验证。
  • 较短扫描时间有助于将90Y PET/CT纳入繁忙的常规临床工作流程。

局限性

  • 需要更大患者队列的研究来确认这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Transarterial radioembolization (TARE) with yttrium-90 (90Y) microspheres is a liver-directed treatment for primary and secondary hepatic malignancies. Personalized dosimetry aims for maximum treatment effect and reduced toxicity. We aimed to compare pre-treatment voxel-based dosimetry from 99mTc macroaggregated albumin (MAA) SPECT/CT with post-treatment 90Y PET/CT for absorbed dose values, and to evaluate image quality of 90Y SiPM-based PET/CT. METHODS: Forty-two patients (28 men, 14 women, mean age: 67 ± 11 years) with advanced hepatic malignancies were prospectively enrolled. Twenty patients were treated with glass and 22 with resin microspheres. Radiation absorbed doses from planning 99mTc-MAA SPECT/CT and post-therapy 90Y PET/CT were assessed. 90Y PET/CT images were acquired for 20 min and reconstructed to produce 5-, 10-, 15-, and 20-min datasets, then evaluated using the 5-point Likert scale. RESULTS: The mean administered activity was 3.44 ± 1.5 GBq for glass and 1.62 ± 0.7 GBq for resin microspheres. The mean tumor absorbed doses calculated from 99mTc-MAA SPECT/CT and 90Y PET/CT were 175.69 ± 113.76 Gy and 193.58 ± 111.09 Gy (P = 0.61), respectively for glass microspheres; they were 60.18 ± 42.20 Gy and 70.98 ± 49.65 Gy (P = 0.37), respectively for resin microspheres. The mean normal liver absorbed doses from 99mTc-MAA SPECT/CT and 90Y PET/CT were 32.70 ± 22.25 Gy and 30.62 ± 20.09 Gy (P = 0.77), respectively for glass microspheres; they were 18.33 ± 11.08 Gy and 24.32 ± 15.58 Gy (P = 0.17), respectively for resin microspheres. Image quality of 90Y PET/CT at 5-, 10-, 15-, and 20-min scan time showed a Likert score of 3.6 ± 0.54, 4.57 ± 0.58, 4.84 ± 0.37, and 4.9 ± 0.3, respectively. CONCLUSIONS: 99mTc-MAA SPECT/CT demonstrated great accuracy for treatment planning dosimetry. SiPM-based PET/CT scanner showed good image quality at 10-min scan time, acquired in one bed position. A PET/CT scan time of 5 min showed acceptable image quality and suffices for dosimetry and treatment verification. This allows for inclusion of 90Y PET/CT in busy routine clinical workflows. Studies with larger patient cohorts are needed to confirm these findings.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Duan H, Khalaf MH, Ferri V, et al. High quality imaging and dosimetry for yttrium-90 (90Y) liver radioembolization using a SiPM-based PET/CT scanner. Eur J Nucl Med Mol Imaging. 2021. PMID: 33443618. doi:10.1007/s00259-021-05188-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。